The Protective Effect Of Different Doses Of Mucosolvan On Lung Function During Perioperative Period Of Lung Cancer

PurposeTo observe the data of perioperative lung cancer,to explore the difference of different doses of Mucosolvan for perioperative lung cancer patients in the treatment of lung function protection,and at the same time to the role of mucosolvan in the clinical treatment of lung cancer and the actual significance of treatment Make further explorations.MethodThrough random selection,90 patients with perioperative lung cancer from September2016 to January 2017 in this hospital were selected as the subject of this study,and the clinical data of all patients during the perioperative period were analyzed.All patients underwent general anesthesia with double-lumen endotracheal intubation.After the onset of anesthesia,lobectomy was performed.On this basis,the groups were grouped according to the different doses of mucosolvan used.Patients with a daily dose of 600 mg were divided into large-dose groups.Patients in this group were treated with600 mg of Mucosolvan daily.The mode of administration was intravenous continuous pumping;Patients with a daily dose of 300 mg were divided into middle-dose groups.The patient received 300 mg of Mucosolvan daily and the intravenous administration method was continuous.The patient with a daily dose of 90 mg was divided into a small dose group.This group of patients received daily 90 mg Mucosolvan treatment.Into.The course of medication for all three groups was 3 days.After the end of treatment,the CRP?C-reactive protein?,TNF-??tumor necrosis factor??,PaO₂?arterial partial pressure of oxygen?,PaO₂ of the three groups after treatment/FiO₂?oxygen and index?and the incidence of complications?including p?Lmonary infections,atelectasis?and other related indicators were compared.Res?Lt?1?After comparison,the preoperative general data?including age,gender,histological type,and surgical site,etc.?and related indicators were not significantly different among the three groups,and all patients did not have any history of thoracotomy.There were no significant differences among all groups in the deaths in the middle or postoperative period,P>0.05,no statistical significance.?2?There were no significant differences in the levels of CRP and TNF-?between the three groups of patients before and after surgery.The CRP indexes of the high-dose group were?6.27±1.25?before and after the operation.Mg/dL,?9.83±2.11?mg/dL,CRP in the middle dose group preoperatively and postoperatively 1 day were?6.21±1.18?mg/dL,?10.17±2.23?mg/dL,respectively,in the low-dose group The CRP indices were?6.23±1.21?mg/dL and?10.85±2.31?mg/dL before and after 1st postoperatively;the TNF-?indices before and after 1 day of the high-dose group were?5.98±1.23?.)fmol/mL,?10.28±1.23?fmol/mL,the TNF-?index before and after the operation in the middle dose group were?6.01±1.29?fmol/mL,?11.12±1.35?fmol/mL,respectively.The TNF-?index was?6.11±1.19?fmol/mL and?11.37±1.49?fmol/mL in the dose group before and after the surgery,respectively;P>0.05,not statistically significant;The CRP and TNF-?levels in the dose group were significantly lower than those in the middle-dose group and the low-dose group.The CRP index of the high-dose group on the3rd day after operation was?8.69±1.64?.)mg/dL,The CRP index of the dose group was?9.85±1.93?mg/dL on the 3rd day after operation,and the CRP index of the low dose group was?9.97±1.95?mg/dL on the 3rd postoperative day;the high dose group was on the 3rd postoperative day.The index of TNF-?was?7.66±1.51?fmol/mL.The TNF-?index in the middle-dose group was?9.85±2.01?fmol/mL on the 3rd day after operation.The TNF-?index in the low-dose group on the 3rd day after operation It was?10.22±2.18?fmol/mL P<0.05,which was statistically significant.The inflammation level in the high-dose group was significantly lower than that in the middle-dose group and the low-dose group at the 3rd postoperative day,P<0.05,which was statistically significant.?3?PaO₂,PaO₂/FiO₂ blood gas parameters were not significantly different between the three groups before surgery and on the 1st postoperative day.Among them,the PaO₂index of the high-dose group was?79.63±5.97?before and after the surgery.?77.81±5.57?.The PaO₂ indices before and after the operation in the middle-dose group were?79.81±5.89?and?77.93±5.64?,respectively.The PaO₂ indices before and after the surgery in the low-dose group were?78.95?.±5.98),?76.83±5.46?;In the high-dose group,the PaO₂/FiO₂ index was?240.63±18.55?and?235.77±16.03?before and after the operation.The patients in the middle-dose group were preoperatively and postoperatively1 day.The PaO₂/FiO₂ index was?241.12±18.21?and?234.18±16.19?,and the PaO₂/FiO₂index before and after the surgery in the low-dose group was?239.78±18.64?and?76.83±5.46?,respectively,P>0.05.There was no statistical significance;on the 3rd postoperative day,the blood gas parameters PaO₂,PaO₂/FiO₂ in the high-dose group showed a significant increase,which was significantly higher than those in the middle-dose group and the low-dose group,P<0.05.,Statistically significant;the blood gas index of the high-dose group was significantly higher than that of the middle-dose group and the low-dose group Among them,the PaO₂ index of the high-dose group was?87.91±6.35?on the 3rd day after operation,PaO₂ index of the middle-dose group on the3rd day?79.34±5.94?,and PaO₂ on the 3rd day after operation in the low-dose group.It was?78.35±5.73?;the PaO₂/FiO₂ index was?268.33±18.62?on the 3rd day after operation in the high-dose group,and the PaO₂/FiO₂ index was?241.69±16.48?on the3rd day after operation in the middle-dose group.The PaO₂/FiO₂ index on the 3rd postoperative day was?238.57±16.31?,P<0.05,which was statistically significant.?4?After treatment with Mucosolvan in the high-dose group,the incidence of p?Lmonary infection was 3.33%,the incidence of atelectasis was 3.33%,and the incidence of complications was 6.67%;patients in the middle-dose group were treated with Mucosolvan The incidence of lung infection was 16.67%,the incidence of atelectasis was 10.00%,and the incidence of complications was 26.67%.After treatment with mucosolvan in the low dose group,the incidence of p?Lmonary infection was16.67%.The incidence of atelectasis was 13.33%,and the complication rate was 30.00%.Compared with the three groups,the risk of p?Lmonary-related complications was relatively low in the high-dose group,and there was a significant difference compared with the middle-dose group and the low-dose group,P<0.05,with statistical significance.in conclusionFor perioperative lung cancer patients,treatment with large doses of Mucosolvan can largely avoid the occurrence of p?Lmonary complications,but also contribute to the reduction of lung inflammation in patients,showing that the drug is in use.In the case of a large dose,it has a good protective effect on the lung function of the patient and can be widely used in clinical treatment in the future.